Anti-CD20 Concabody Study: MPZL1 Target and Cell Death Efficacy in CLL

A 118.8 KB PDF research article authored by A-Yeon Choi and published on figshare in April 2026. The work identifies MPZL1 as a novel regulator of antibody-induced cell death and evaluates the efficacy of engineered 'concabody' fusion proteins. Experiments include in vitro assays and ex vivo tests using peripheral blood mononuclear cells from chronic lymphocytic leukemia patients.

Use Cases

• Analyzing molecular mechanisms of antibody-induced direct cell death based on the described MPZL1 target.
• Evaluating the design and efficacy of bioengineered antibody-lectin fusion proteins (concabodies) based on the described in vitro and ex vivo results.
• Studying lysosomal membrane permeabilization as a cell death characteristic based on the mechanistic studies described.
• Investigating antibody-dependent cellular cytotoxicity enhancement strategies based on the concabody performance described.

Strengths

• Data is openly licensed under CC-BY-4.0.
• The research is recent, with a last update timestamp of 2026-04-15.
• The description provides a detailed account of the study's methods, results, and discussion.

Limitations

• The dataset is a single 118.8 KB PDF file, which is a very small-scale publication.
• Column-level documentation and sample data are unavailable; the content is a research article.
• The row count and specific data formats beyond the PDF are unknown.

Provenance

Source

figshare, authored by A-Yeon Choi.

Collection Method

Research article detailing experimental methods including antibody–APEX2 proximity labeling, mechanistic studies, and ex vivo patient sample assays.

Time Range

Study publication date is 2026.

Freshness

Last updated 2026-04-15 04:36:55.

Geography

null